Company Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).
The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease.
The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.
Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Dec 8, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 422 |
| CEO | Ryan Watts |
Contact Details
Address: 161 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 866 8547 |
| Website | denalitherapeutics.com |
Stock Details
| Ticker Symbol | DNLI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001714899 |
| CUSIP Number | 24823R105 |
| ISIN Number | US24823R1059 |
| Employer ID | 46-3872213 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan J. Watts Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Alexander O. Schuth M.D. | Co-Founder, Chief Financial Officer, Chief Operating Officer and Secretary |
| Dr. Marc Tessier-Lavigne Ph.D. | Co-Founder and Independent Director |
| Dr. Carole Ho M.D. | Chief Medical Officer and Head of Development |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer |
| Joe Lewcock Ph.D. | Chief Scientific Officer |
| Chris Walsh J.D. | General Counsel |
| Cindy Dunkle | Chief People Officer |
| Katie Peng | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 3, 2025 | 8-K | Current Report |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 17, 2025 | ARS | Filing |
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 2, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |